Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nabilone for Severe Behavioural Problems in Adults With Intellectual and Developmental Disabilities
NCT05273320Phase 1Completed
- Start
- Mar 2022
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nabilone in behavioral disorder. Primary endpoint: Incidence of Treatment-Emergent Physical Adverse Events Assessed by the UKU Side Effect Rating Scale at 9 weeks. Started Mar 2022; status: completed.
02
Drugs
nabilone
03
Conditions
behavioral disorder
Beyond the preview
Go deeper on NCT05273320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05273320.